About BioDuro
BioDuro, a PPD company, is a leading life sciences research organization that provides biopharmaceutical clients with comprehensive, integrated drug discovery services spanning target identification through Phase 0. With depth and breadth of therapeutic expertise in small molecule discovery combined with proprietary technology platforms, BioDuro is uniquely positioned to help its clients significantly accelerate their lead discovery programs.
Founded in 2005, BioDuro has more than 600 employees, the majority of whom are based in Beijing, China, where the company operates a state-of-the-art, 110,000-square-foot laboratory. BioDuro has built a team of highly experienced and educated researchers and scientists, 25 percent of whom have a Ph.D. and 15 percent of whom have been trained overseas.
With the highest concentration of drug discovery expertise of any contract research organization (CRO) in China and a broad range of capabilities in chemistry, discovery biology, drug metabolism and pharmacokinetics (DMPK), pharmacology, as well as integrated preclinical research and development services, BioDuro brings superior insight and innovative solutions to its clients’ drug discovery programs.
Through a strategic partnership with X-Chem Inc., BioDuro is able to conduct innovative hit and lead generation by using its proprietary DNA-based chemical libraries, giving the clients access to large, diverse libraries of compounds that can be used to better interrogate a broad range of high priority drug targets, which can significantly accelerate lead discovery and improve the probability of success.
In November 2009, BioDuro joined PPD, a leading global CRO providing drug discovery, development and life cycle management services. Together, PPD and BioDuro offer a broad range of research and development services for biopharmaceutical clients from early stage through post-approval. To learn more about PPD, visit the company’s website.
关于保诺
作为PPD的子公司，保诺科技（北京）有限公司（简称“保诺”）是一家业界领先的合同研究组织（CRO），为全球生物制药业客户提供从确认药物靶点直至临床前试验的全面整合的一体化药物研发服务。凭借在各个疾病治疗领域的深厚专长和先进的技术平台，保诺能够帮助客户大大加快药物发现的进程。
保诺成立于2005年，在北京拥有一座先进的实验大楼，占地面积大约为1.1万平方米，为客户提供化学、药物研究生物学、药物代谢动力学、药理学以及整合药物研发服务。保诺的员工数量大约有600余人，其中大多数在北京的实验室工作。此外，保诺目前正在上海兴建一个全资子公司，新投资兴建的实验室大楼面积约5000平方米。在上海的新实验室，保诺将进一步扩建公司目前在化学、药物研究生物学、药物代谢动力学和药理学领域的服务能力，并建造一个世界一流的动物房，招募新员工，继续服务更多客户。
保诺已经组建了一支世界级药物研发团队，其中20％的研究人员拥有博士学位，15％曾有国外学习和工作的经历。在中国，与业界同行相比，保诺聚集了众多药物研发领域的精英，有能力为客户的药物研发项目提供卓越的创新解决方案。
保诺一直致力于应用创新技术来加快药物的发现。因此，我们与X-Chem公司建立了战略合作伙伴关系。X-Chem公司拥有一个新型的基于DNA化合物库技术平台，通过使用该技术平台，保诺的客户能够显著加快先导化合物发现和扩展靶点范围， X-Chem公司的专有化学、库设计与合成以及先导化合物筛选能力可以帮助从不同化合物类中识别到最有活性的先导化合物，从而极大地提高药物发现的成功概率。
2009年11月，保诺被美国PPD公司收购，成为PPD在华的一个子公司。PPD是一家世界领先的CRO公司，为全球制药业的客户提供药物发现、临床试验、药物批准上市后服务。现在， PPD和保诺的服务完美整合并广泛覆盖药物研发各个阶段，能够为我们的客户提供药物发现直至IV期临床试验和药物批准上市后服务。想要了解PPD和保诺的更多信息，请访问PPD的官方网站（www.ppdi.com）和保诺的官方网站（www.bioduro.com）。
